Comparing Revenue and Profitability of Johnson & Johnson and Pfizer
JNJ Johnson & Johnson
$278.70 -1.36%
View chart & analysis → - 1Johnson & Johnson shows a stronger profit profile than Pfizer, maintaining consistently high absolute revenue across all reporting periods.
- 2Pfizer's quarterly revenue showed volatility, ranging between $13.7 billion and $17.8 billion over eight quarters.
- 3Johnson & Johnson signed a definitive agreement to acquire Olin Biosciences, involving an upfront acquisition cost of $2.2 billion.
So what's the key point?
Johnson & Johnson has had more steady revenue and better profits than Pfizer. Johnson & Johnson has agreed to buy Olin Biosciences for $2.2 billion.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.